8-K/AEarnings & ResultsExhibits & Filings

BRISTOL MYERS SQUIBB CO 8-K/A Report, Financial Results (Dec 1, 2005)

Filed December 1, 2005For Securities:BMYCELG-RIBMYMP

Summary

This filing is an amendment to a previous Form 8-K filed by Bristol-Myers Squibb Company (BMY) on October 28, 2005. The amendment primarily revises and furnishes supplemental financial information previously posted on the company's website. This supplemental information, incorporated by reference as Exhibit 99.2, now includes updated net sales, months on hand, and demand data for key products across its International Pharmaceuticals, Mead Johnson Nutritionals, and Related Healthcare segments as of September 30, 2005, June 30, 2005, and March 31, 2005. For investors, this amendment signifies a refinement of previously disclosed data related to operational performance and inventory levels for key product lines. The updated information provides a more granular view of sales trends and inventory management across major business segments, allowing for a more informed assessment of the company's recent performance and operational efficiency. Investors should review the revised supplemental information to understand any changes in product demand and inventory status that could impact future financial results.

Key Highlights

  • 1Amendment to a prior Form 8-K filing concerning Q3 2005 results.
  • 2Revision and re-furnishing of supplemental financial information originally posted on the company website.
  • 3Updated data includes net sales, months on hand, and demand information for key products.
  • 4Information is broken down by reporting segments: International Pharmaceuticals, Mead Johnson Nutritionals, and Related Healthcare.
  • 5Data covers multiple recent periods: September 30, 2005, June 30, 2005, and March 31, 2005.
  • 6The revised supplemental information is incorporated by reference as Exhibit 99.2.

Frequently Asked Questions

This filing is an amendment to a previous Form 8-K. Its main purpose is to revise and re-furnish supplemental financial information that was previously available on Bristol-Myers Squibb's website, providing updated details on net sales, inventory levels ('months on hand'), and product demand across key business segments for specific periods.

The revised supplemental information includes updated figures for net sales, months on hand (which indicates inventory levels), and demand data for key products within the International Pharmaceuticals, Mead Johnson Nutritionals, and Related Healthcare reporting segments.

The updated data in the supplemental information covers three specific points in time: September 30, 2005, June 30, 2005, and March 31, 2005.

The revised supplemental information is furnished as Exhibit 99.2 to this Form 8-K/A filing and was also originally posted on the Bristol-Myers Squibb Company's website at www.bms.com.